Bristol Myers Squibb's S1P Receptor Modulator Zeposia Achieves Dual Primary Endpoints in Phase 3 Trial for Moderate to Severe Ulcerative Colitis

Today, Bristol-Myers Squibb announced that its sphingosine-1-phosphate (S1P) receptor modulator, Zeposia (ozanimod), met both primary endpoints in pivotal Phase 3 trials for the induction and maintenance treatment of adults with moderately to severely active ulcerative colitis. The results demonstrated highly statistically significant efficacy (p<0.0001) for clinical remission at Week 10 following induction therapy and for maintenance therapy at Week 52. According to the press release, this marks the first oral S1P receptor modulator to demonstrate positive results in Phase 3 clinical studies for the treatment of patients with moderately to severely active ulcerative colitis.

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) characterized by persistent abnormal immune responses that cause sustained inflammation and ulceration of the colonic mucosa. Symptoms include bloody stools, severe diarrhea, and frequent abdominal pain. Ulcerative colitis significantly impacts patients’ health-related quality of life, affecting physical functioning, social and emotional well-being, and work capacity. It is estimated that 12.6 million people worldwide are affected by IBD.

Zeposia (ozanimod) is an oral sphingosine-1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. It received FDA approval this year for the treatment of patients with multiple sclerosis. Currently, the mechanism by which Zeposia exerts its therapeutic effect in ulcerative colitis has not been fully elucidated, but it may involve reducing lymphocyte migration to the inflamed intestinal mucosa.

“Patients with ulcerative colitis struggle to effectively manage this often unpredictable and potentially debilitating disease,” said Dr. Samit Hirawat, Chief Medical Officer of Bristol-Myers Squibb Company. “For patients with moderate-to-severe ulcerative colitis, the clinical trial results for Zeposia are encouraging, suggesting that Zeposia may become an oral treatment option with a more favorable benefit-risk profile.”

Bristol-Myers Squibb will present the detailed results of this study at upcoming medical conferences. The company is also exploring the efficacy of Zeposia in treating moderate-to-severe active Crohn’s disease through its ongoing Phase 3 YELLOWSTONE clinical trial program.

Original Title: Bristol-Myers Squibb’s S1P Receptor Modulator Meets Dual Phase 3 Clinical Endpoints in the Treatment of Moderate-to-Severe Ulcerative Colitis

*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.

▽Follow [WuXi AppTecDe】WeChat Official Account